Neurocrine Biosciences (NASDAQ: NBIX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Neurocrine Biosciences reported 50 open-market sales of 498,649 shares ($77.4m) and 0 open-market purchases, by 14 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Neurocrine Biosciences shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,226	$164.74	15,560	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−908	$165.71	14,652	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,466	$166.77	13,186	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,500	$167.72	11,686	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,300	$168.53	10,386	Form 4
3 November 2026	Morrow George J	Director	Option exercise, 10b5-1 plan	+7,200	$53.64	17,586	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−100	$158.18	17,486	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−100	$162.05	17,386	Form 4
3 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−600	$163.71	16,786	Form 4
2 November 2026	Morrow George J	Director	Option exercise, 10b5-1 plan	+7,500	$53.64	17,886	Form 4
2 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,900	$144.98	15,986	Form 4
2 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−4,300	$145.86	11,686	Form 4
2 November 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−1,300	$146.76	10,386	Form 4
1 November 2026	Gano Kyle	Chief Executive Officer	Option exercise	+614	—	155,342	Form 4
1 November 2026	Gano Kyle	Chief Executive Officer	Shares withheld for tax	−332	$146.10	155,010	Form 4
30 October 2026	Morrow George J	Director	Option exercise, 10b5-1 plan	+300	$53.64	10,686	Form 4
30 October 2026	Morrow George J	Director	Open-market sale, 10b5-1 plan	−300	$149.00	10,386	Form 4
14 September 2026	Abernethy Matt	Chief Financial Officer	Open-market sale, 10b5-1 plan	−2,311	$157.20	42,808	Form 4
14 September 2026	Boyer David W.	Chief Corp. Affairs Officer	Open-market sale, 10b5-1 plan	−826	$157.45	8,722	Form 4
11 September 2026	Gorman Kevin Charles	Director	Grant or award	+14,343	—	525,636	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Neurocrine Biosciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.